Evidence map›Paper›PMID 40129501›Full record

ArticleMolecular therapy. Nucleic acids2025

Jennifer Khirallah, Hanan Bloomer, Douglas Wich, Changfeng Huang, J Noah Workman, Yamin Li, Gregory A Newby, David R Liu, Qiaobing Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. In vivo base editing of Asgr1 reduces blood lipids in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jennifer KhirallahDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
Hanan BloomerDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
Douglas WichDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
Changfeng HuangDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
J Noah WorkmanDepartment of Genetic Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Yamin LiDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.
Gregory A NewbyDepartment of Genetic Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
David R LiuMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Qiaobing XuDepartment of Biomedical Engineering, Tufts University, Medford, MA 02155, USA.

Funding

In vivo precision genome editing to correct genetic diseaseR00HL163805 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI NEWBY, GREGORY A. · 2023 to 2025
$747k
NHLBI NIH HHS R00 HL163805
6 · The paper itself

Abstract

Cardiovascular disease (CVD) is the leading cause of death globally and is exacerbated by elevated blood levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs). Existing approaches for decreasing blood lipid levels rely on daily medications, leading to poor patient adherence. Gene therapy represents a promising "one and done" strategy to durably reduce blood lipid levels.

Indexed as

angiopoietin-like protein-3base editingcardiovascular diseaseCRISPR-Cas9gene editinglipid nanoparticleMT: RNA/DNA Editing

Identifiers

PMID40129501
PMCPMC11932681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.